LG Chem is deepening its collaboration with both the LG AI Research Institute and external biotech firms to accelerate AI-driven drug discovery, according to industry sources on September 27th. The LG AI Research Institute, founded in 2020, specializes in developing AI technologies aimed at enhancing the global competitiveness of various LG subsidiaries, including LG Chem.

One of the key tools in this collaboration is the "EXAONE" platform, developed by the LG AI Research Institute. By utilizing this AI platform, LG Chem can extract crucial data from complex chemical experiments and run virtual simulations to propose optimal experimental conditions, significantly boosting research efficiency. Industry experts view this collaboration as pivotal in accelerating digital transformation and enhancing global competitiveness.

In August, LG Chem signed a joint research agreement with Galux, an AI-driven drug design company, to develop anti-cancer drugs. Galux will design protein lead compounds aimed at overcoming the limitations of current treatments, while LG Chem will optimize these compounds and carry out preclinical and global clinical trials.

Founded in 2020, Galux applies natural scientific principles to molecular properties to develop AI drug design solutions. In 2023, the company received investment from LG and was selected for the Ministry of SMEs and Startups' "Super-gap Startup 1000+ Project" in the bio-health sector.

Through this partnership, LG Chem aims to shorten drug development timelines and secure differentiated new compounds. In the bio sector, LG affiliates have used AI to analyze protein structures of drug candidates, verifying over 1,000 substances within just six months, drastically speeding up drug discovery efforts.

An LG Chem representative told Hit News, "We are collaborating with the LG AI Research Institute on AI-related projects and, externally, with Galux to shorten drug development timelines. Moving forward, we plan to prioritize collaboration with the LG AI Research Institute in AI-related initiatives."